# Vir Biotechnology, Inc. (VIR) insider trading

> In the 12 months to Nov 17, 2026, 9 VIR insiders reported open-market sales of $8.2M across 27 filings; no open-market purchases were filed.

Canonical: https://massive.com/quote/vir/insider-trading
Latest filing: 2026-11-04 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $8.2M | 27 filings · 9 insiders |
| Open-market purchases | $0 | 0 filings |
| Pre-arranged sales (10b5-1) | 27 of 27 | All $8.2M sold was pre-arranged |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| SVF Endurance (Cayman) Ltd | 10% owner | $4.1M | — | 2 | 100% of sales | 2025-12-03 |
| Vicki L. Sato | Director | $1.5M | — | 7 | 100% of sales | 2026-05-04 |
| SOFTBANK VISION FUND (AIV M1) L.P. | 10% owner | $1.2M | — | 1 | 100% of sales | 2025-12-01 |
| Backer Marianne De | Chief Executive Officer → President and CEO | $947.0K | — | 3 | 100% of sales | 2026-04-07 |
| Verneuil Vanina de | EVP, General Counsel, Corp Sec | $239.3K | — | 3 | 100% of sales | 2026-11-04 |
| Brent Sabatini | SVP, Chief Accounting Officer | $113.1K | — | 5 | 100% of sales | 2026-06-02 |
| Jason O'Byrne | EVP & Chief Financial Officer | $68.9K | — | 3 | 100% of sales | 2026-02-26 |
| Mark Eisner | EVP and Chief Medical Officer | $49.5K | — | 2 | 100% of sales | 2026-02-26 |
| Janet Napolitano | Director | $30.2K | — | 1 | 100% of sales | 2026-06-02 |

## Open-market trades by filing

27 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Avg price | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-11-04 | 2026-11-02 | Verneuil Vanina de | EVP, General Counsel, Corp Sec | Sale (10b5-1) | 3,750 | $11.18 | $41.9K | 110,193 | — |
| 2026-06-02 | 2026-06-01 | Brent Sabatini | SVP, Chief Accounting Officer | Sale (10b5-1) | 379 | $9.45 | $3.6K | 61,902 | — |
| 2026-06-02 | 2026-06-01 | Janet Napolitano | Director | Sale (10b5-1) | 3,200 | $9.45 | $30.2K | 21,216 | — |
| 2026-05-04 | 2026-05-01 | Vicki L. Sato | Director | Sale (10b5-1) | 22,000 | $10.05 | $221.0K | 1,078,391 | — |
| 2026-04-07 | 2026-04-06 | Backer Marianne De | President and CEO | Sale (10b5-1) | 72,559 | $9.16 | $664.4K | 948,145 | — |
| 2026-04-02 | 2026-04-01 | Vicki L. Sato | Director | Sale (10b5-1) | 22,000 | $9.07 | $199.6K | 1,100,391 | — |
| 2026-03-24 | 2026-03-23 | Brent Sabatini | SVP, Chief Accounting Officer | Sale (10b5-1) | 7,711 | $9.12 | $70.3K | 61,902 | — |
| 2026-03-03 | 2026-03-02 | Vicki L. Sato | Director | Sale (10b5-1) | 22,000 | $9.51 | $209.2K | 1,122,391 | — |
| 2026-02-26 | 2026-02-24 | Backer Marianne De | Chief Executive Officer | Sale (10b5-1) | 14,762 | $9.53 | $140.7K | 1,020,704 | — |
| 2026-02-26 | 2026-02-24 | Verneuil Vanina de | EVP, General Counsel, Corp Sec | Sale (10b5-1) | 16,817 | $9.77 | $164.2K | 112,982 | — |
| 2026-02-26 | 2026-02-24 | Mark Eisner | EVP and Chief Medical Officer | Sale (10b5-1) | 3,505 | $9.69 | $34.0K | 154,024 | — |
| 2026-02-26 | 2026-02-24 | Jason O'Byrne | EVP & Chief Financial Officer | Sale (10b5-1) | 1,634 | $9.53 | $15.6K | 162,615 | — |
| 2026-02-26 | 2026-02-24 | Brent Sabatini | SVP, Chief Accounting Officer | Sale (10b5-1) | 1,430 | $9.53 | $13.6K | 69,613 | — |
| 2026-02-26 | 2026-02-24 | Vicki L. Sato | Director | Sale (10b5-1) | 42,377 | $9.75 | $413.4K | 1,144,591 | — |
| 2026-02-24 | 2026-02-23 | Backer Marianne De | Chief Executive Officer | Sale (10b5-1) | 19,039 | $7.45 | $141.9K | 1,035,466 | — |
| 2026-02-24 | 2026-02-23 | Verneuil Vanina de | EVP, General Counsel, Corp Sec | Sale (10b5-1) | 4,445 | $7.45 | $33.1K | 129,799 | — |
| 2026-02-24 | 2026-02-23 | Mark Eisner | EVP and Chief Medical Officer | Sale (10b5-1) | 2,089 | $7.45 | $15.6K | 157,529 | — |
| 2026-02-24 | 2026-02-23 | Jason O'Byrne | EVP & Chief Financial Officer | Sale (10b5-1) | 2,089 | $7.45 | $15.6K | 164,249 | — |
| 2026-02-24 | 2026-02-23 | Brent Sabatini | SVP, Chief Accounting Officer | Sale (10b5-1) | 1,829 | $7.45 | $13.6K | 71,043 | — |
| 2026-02-18 | 2026-02-13 | Brent Sabatini | SVP, Chief Accounting Officer | Sale (10b5-1) | 1,530 | $7.79 | $11.9K | 47,872 | — |
| 2026-02-03 | 2026-02-02 | Vicki L. Sato | Director | Sale (10b5-1) | 22,000 | $7.71 | $169.7K | 1,144,391 | — |
| 2026-01-05 | 2026-01-02 | Vicki L. Sato | Director | Sale (10b5-1) | 22,000 | $5.93 | $130.4K | 1,166,391 | — |
| 2025-12-03 | 2025-12-01 | SVF Endurance (Cayman) Ltd | 10% owner | Sale (10b5-1) | 191,854 | $5.98 | $1.1M | 13,728,924 | — |
| 2025-12-02 | 2025-12-01 | Vicki L. Sato | Director | Sale (10b5-1) | 22,000 | $6.00 | $132.1K | 1,188,391 | — |
| 2025-12-01 | 2025-11-26 | SOFTBANK VISION FUND (AIV M1) L.P. | 10% owner | Sale (10b5-1) | 189,431 | $6.41 | $1.2M | 13,920,778 | — |
| 2025-11-26 | 2025-11-24 | SVF Endurance (Cayman) Ltd | 10% owner | Sale (10b5-1) | 463,774 | $6.27 | $2.9M | 14,110,209 | — |
| 2025-11-18 | 2025-11-17 | Jason O'Byrne | EVP & Chief Financial Officer | Sale (10b5-1) | 6,799 | $5.56 | $37.8K | 110,701 | — |

## Other insider activity (not market trades)

- Option exercises: 1 record
- Grants and awards: 15 records
- Other: 6 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Pre-arranged (10b5-1)**: The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- **Role**: The title on each filing. Someone whose title changed shows more than one.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
- **Counted once**: When several owners (a fund and its partners, say) report the same trade, it's counted once. Corrected filings replace the originals.

## FAQ

### Has Vir Biotechnology, Inc.'s CEO sold stock?

Yes. Backer Marianne De (CEO) sold 106,360 shares ($947.0K) between Feb 2026 and Apr 2026, all under a pre-arranged 10b5-1 plan.

### How current is VIR’s insider data?

These are VIR Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The VIR Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=VIR&filing_date.gte=2025-11-17&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Vir Biotechnology, Inc. (VIR) stock price](https://massive.com/quote/vir.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
